Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?

Figure 1

Interactions between gene products and OADs on target organs. Genes and the related “at-risk” SNPs (in brackets) are shown in the upper part. Arrows indicate if a SNP has a negative impact on the responsiveness to a given drug in a specific organ. Red arrows indicate increased drug resistance (or altered drug metabolism), whereas green arrows indicate a beneficial effect of such a SNP. Dashed lines indicate side effects of a given drug. TZD = thiazolidinedione; SU = sulphonylureas; MET = metformin.